ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0399

External Validation of Claims-based Algorithms for Newly Diagnosed Juvenile Idiopathic Arthritis

Daniel Horton1, Lauren Parlett2, Yuyang Zhu3, Sanika Rege4, Patricia Hoffman5, Daniel Reiff6, Sarah McGuire7, Sonia Pothraj8, Cynthia Salvant9, Lakshmi Moorthy1, Cecilia Huang4, Dawn Koffman4, Matthew Iozzio3, Alicia Iizuka4, Kevin Schott2, Stephen Crystal10, Amy Davidow11, Tobias Gerhard4, Kevin Haynes12, Brian Strom13, Daniel Beachler2 and Carlos Rose14, 1Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 2Carelon Research, Inc, Wilmington, DE, 3Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA, New Brunswick, 4Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA, New Brunswick, NJ, 5Hospital for Special Surgery, New York, NY, 6Boys Town National Research Hospital, Boys Town, 7Department of Obstetrics and Gynecology, Cooper Medical School, Camden, Camden, NJ, 8Washingtonville Pediatrics, Washingtonville, NY, 9Albany Medical Center, Albany, NY, 10Rutgers Center for Health Services Research, Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, 11New Jersey Medical School, Newark, NJ, 12Janssen Research & Development, Titusville, NJ, 13Rutgers Biomedical and Health Sciences, New Brunswick, 14Thomas Jefferson University, Wilmington, DE

Meeting: ACR Convergence 2025

Keywords: Administrative Data, Epidemiology, Juvenile idiopathic arthritis, population studies, Statistical methods

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0387–0429) Pediatric Rheumatology – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Administrative claims databases enable research in large populations with JIA. We previously showed that machine learning (ML)-based algorithms accurately identify new JIA diagnoses within US commercial insurance claims data. We externally validated these algorithms within US public insurance claims data.

Methods: We performed a cross-sectional validation study using US commercial health plan data (2013-20) and national US Medicaid data (2013-18). We identified children diagnosed with JIA (ICD-9-CM: 696.0, 714, 720; ICD-10-CM: L40.5, M05, M06, M08, M45) before age 18 after ≥12 months’ continuous enrollment without JIA diagnosis or immunosuppression. JIA diagnoses were based on 3 previously validated definitions: 1) rheumatologist’s diagnosis plus ≥2 specific lab test orders; 2) ≥2 outpatient diagnoses 8-52 weeks apart; or 3) 1 inpatient diagnosis. A random set of available qualifying charts were abstracted and independently adjudicated as definite, probable, possible, or unlikely JIA by clinical experts; discrepancies were resolved by consensus. Incident JIA was defined as definite or probable JIA diagnosed ≤4 months before first JIA claim. ML-based algorithms used simulation-based balancing and logistic regression regularization hyperparameters with 10-fold cross-validation. We used optimal predictive model variables to assess sensitivity (Se), specificity (Sp), and positive predictive value (PPV) (95% confidence interval [CI]). We also tested rule-based algorithms refined based on provider type, JIA diagnosis counts, laboratory test counts, and documented JIA treatment. We compared results across databases and ICD types.

Results: Of 298 eligible charts reviewed (182 commercial, 116 public), 151 had incident JIA (ICD-9 commercial 58%, public 53%; ICD-10 commercial 41%, public 52%). Optimal ML-based algorithms derived within commercial claims data enabled excellent discrimination between incident JIA and unlikely JIA (ICD-9: Se 100%, Sp 96%, PPV 97%; ICD-10: Se 100%, Sp 97%, PPV 97%) (Table 1). However, the same algorithm was not accurate within the Medicaid sample (ICD-9: Se 97%, Sp 19%, PPV 67%; ICD-10: Se 100%, Sp 29%, PPV 70%), and more accurate algorithms derived within Medicaid data used distinct sets of predictive variables (Table). Moreover, optimal ML-based algorithms differed in number and types of predictors across ICD-9 and ICD-10 data. Rule-based algorithms had lower specificity and/or sensitivity, but refined algorithms were more accurate and consistent across databases and ICD types (Table 2-3). Preferred rule-based algorithms required either: 1) rheumatologist’s outpatient diagnosis plus ≥4-5 specific lab orders, or 2) ≥5 outpatient JIA visits (first diagnosis not for eye care) plus any JIA treatment.

Conclusion: While ML-based diagnostic algorithms for incident JIA performed well within each database and ICD type, results differed across databases and ICD types. In contrast, refined rule-based algorithms had better external validity, with similarly high PPVs across databases and ICD code types. These preferred rule-based algorithms will improve the quality of future claims-based research on the diagnosis, management, and outcomes of newly diagnosed JIA.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: D. Horton: None; L. Parlett: Bristol-Myers Squibb(BMS), 5, Novartis, 5, Pfizer, 5, Teva, 5; Y. Zhu: None; S. Rege: None; P. Hoffman: None; D. Reiff: None; S. McGuire: None; S. Pothraj: None; C. Salvant: None; L. Moorthy: None; C. Huang: None; D. Koffman: None; M. Iozzio: None; A. Iizuka: None; K. Schott: None; S. Crystal: None; A. Davidow: None; T. Gerhard: Genentech, 1; K. Haynes: Janssen, 3, 11; B. Strom: None; D. Beachler: None; C. Rose: None.

To cite this abstract in AMA style:

Horton D, Parlett L, Zhu Y, Rege S, Hoffman P, Reiff D, McGuire S, Pothraj S, Salvant C, Moorthy L, Huang C, Koffman D, Iozzio M, Iizuka A, Schott K, Crystal S, Davidow A, Gerhard T, Haynes K, Strom B, Beachler D, Rose C. External Validation of Claims-based Algorithms for Newly Diagnosed Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/external-validation-of-claims-based-algorithms-for-newly-diagnosed-juvenile-idiopathic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/external-validation-of-claims-based-algorithms-for-newly-diagnosed-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology